Genmab — April 2020

[E_L]

anybody got the current UBS target price? yesterday:
UBS Reiterates Neutral Rating on Genmab A/S https://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Neutral+Rating+on+Genmab+AS+(GEN%3ADC)+(GMAB)/16717644.html

[GeorgeBest]

I think it is 1460 or 1480.

[kkjoel]

I have 1460 as well.

[kkjoel]

But no date on
when it was set.

[GeorgeBest]

Very recently

[GeorgeBest]

But Genmab also figure on the UBS Most Preffered List for European Pharma and Biotech Stocks.

[E_L]

thks

[E_L]

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) https://www.globenewswire.com/news-release/2020/04/08/2013405/0/en/Regeneron-and-Zai-Lab-Announce-Regional-Strategic-Collaboration-for-REGN1979-CD20xCD3-Bispecific-Antibody.html

[E_L]

Barclays Reiterates Overweight Rating on Genmab A/S (GEN:DC) (GMAB)

[E_L]

analysts are also bored

[E_L]

shame we don't have one of these: Karyopharm Launches Multiple Myeloma Drug Selinexor in COVID-19 Clinical Trial https://www.myelomacrowd.org/karyopharm-launches-multiple-myeloma-drug-selinexor-in-covid-19-clinical-trial/

[gdn55]

Det er modigt efter min mening at sælge ud her op til påskeferien. Der kunne jo blive afsluttet en aftale her i påsken.

[bibob]

Så længe har forskere kendt til smittefare ved flagermus. https://nyheder24.dk/nyheder/saa-laenge-har-forskere-kendt-til-smittefare-ved-flagermus

[Solsen]

NBI (biotech) vel kun godt 10% ned fra ATH. Dommedagsprofeterne er tæt på eufori og aktierne stiger. God påske !

[JKY_VH]

På den lange bane har aktier en underlukkende positiv trend. God påske til alle også mørkemænd, hulemænd og dommedagsprofeter:-)

[GeorgeBest]

Sanders trækker sig som kandidat. Så slipper vi da i det mindset for at høre på hans felttog mod pharma/biotech selskaber i valgkampen

[JKY_VH]

hov underliggende:-)

[E_L]

Systemic amyloidosis: moving into the spotlight https://www.nature.com/articles/s41375-020-0802-4 https://sci-hub.tw/https://www.nature.com/articles/s41375-020-0802-4

[E_L]

https://sci-hub.tw/https://www.nature.com/articles/s41375-020-0802-4

[E_L]

The provisional response rates are
incredibly promising and suggest that the combination of
daratumumab with CyBorD could represent a significant
advance in the treatment of AL amyloidosis assuming results

are confirmed in the ongoing phase III study.